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Melanie Meyer-Luehmann et al. recently reported 
that amyloid plaques form extremely rapidly-within 
one day, in three mouse models of Alzheimer’s disease 
studied longitudinally in vivo [1]. However, the ‘rapid 
appearance’ of ‘newborn’ amyloid plaques can also be 
the result of delayed visualization of existing amyloid 
plaques, which is caused by the increase in the con-
centration of methoxy-XO4, an amyloid indicator (Fig. 
1). The fact that the authors did not find any growth of 
the ‘newborn’ amyloid plaques supports this notion.  
Most compounds taken up by brain show dif-
ferent regional and time-dependent distributions in 
the human brain revealed by PET [2, 3] and the time 
for reaching peak concentrations of compounds in 
CNS can vary from minutes to days after administra-
tion [3]. It is unclear, however, whether methoxy-XO4 
is distributed evenly across the brain and when the 
brain concentration of methoxy-XO4 reaches the peak 
during the 1-7 day time course after an intraperitoneal 
injection. Using multiphoton microscopy, the kinetics 
of another amyloid indicator, Pittsburgh compound B 
(PIB) was studied in an Alzheimer’s disease mouse 
model  using an intravenous injection. The uneven 
distribution and the concentration change of PIB were 
clearly shown in the small brain areas, particularly in 
the vicinity of small blood vessels. Interestingly, the 
concentration of PIB in some small areas even kept 
increasing after their neighbor areas reached the con-
centration peak of PIB, indicating that the perfusion of 
PIB from the high concentration area to the low con-
centration area takes place all the time in brain [4]. 
While uneven distribution of methoxy-XO4 in the 
brain may occur after an intraperitoneal injection, this 
distribution is not comparable to PIB because within 
minutes PIB levels reach saturation across the brain 
after an intravenous injection. However, the kinetics of 
intraperitoneally-administered methoxy-XO4 in the 
blood and the brain should be studied, in particular, an 
intraperitoneal injection of a ~5,000-fold higher dose of 
amyloid indicator than the doses used in PET or 
SPECT studies may provide a high concentration pool 
of methoxy-XO4 in the abdominal cavity and delay 
methoxy-XO4 to reach its peak in certain brain areas. 
From our point of view, it is still early to conclude that 
newly visualized amyloid plaques are ‘newborn’ be-
fore confirming that the concentration of methoxy-XO4 
does not increase in the area where ‘newborn’ amyloid 
plaques appear. 
 
Fig.1. A possible interpretation for ‘rapid appearance’ of amy-
loid plaques. An existing amyloid plaque not detected in day 1 
can be detected by the increase in the concentration of meth-
oxy-XO4 in day 2. Arrowhead, undetected amyloid plaque; 
Arrow, detected amyloid plaque. Int. J. Biol. Sci. 2008, 4 
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